103882-84-4

Usage

Uses

Used in Anticancer Applications:
Gemcitabine is used as an anticancer agent for the treatment of solid tumors. It is particularly effective against a wide range of malignancies, including pancreatic, non-small cell lung, breast, ovarian, and bladder cancers. The drug works by inhibiting DNA synthesis, which prevents the cancer cells from dividing and proliferating, thereby slowing down tumor growth and progression.
Used in Combination Therapies:
Gemcitabine is often used in combination with other chemotherapeutic agents to enhance the overall effectiveness of cancer treatment. The synergistic action of gemcitabine with other drugs can help overcome drug resistance, increase chemo-sensitivity, and improve the therapeutic outcomes for patients with various types of solid tumors.
Used in Personalized Medicine:
Gemcitabine's effectiveness can be tailored to individual patients based on their specific genetic and molecular profiles. This personalized approach allows for the optimization of treatment regimens, minimizing side effects and maximizing the potential for successful cancer treatment.
Used in Drug Delivery Systems:
To improve the bioavailability, delivery, and therapeutic outcomes of gemcitabine, various drug delivery systems have been developed. These systems, which include liposomes, nanoparticles, and polymeric carriers, aim to enhance the drug's solubility, stability, and targeted delivery to cancer cells, thereby reducing systemic toxicity and improving patient compliance.

InChI:InChI=1/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1

Upstream product

• 134877-42-2 3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-1-O-methanesulfonyl-D-erythro-pentofuranose 
• 122111-01-7 2-deoxy-2,2-difluoro-D-erythro-pentonic acid γ-lactone 3,5-dibenzoate 
• 1173824-58-2 (2R,3R)-2-((benzoyloxy)methyl)-4,4-difluoro-5-hydroxyoxolan-3-yl benzoate 
• 143157-23-7 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-acetamidopyrimidin-2-one 

Downstream Products

• 122111-03-9 gemcitabine hydrochloride 
• 95058-81-4 gemcitabine 
• 116371-67-6 Gemcitabine monophosphate 
• 122111-05-1 2'-deoxy-2',2'-difluorocytidine hydrochloride 
• 114248-23-6 Deoxydifluorouridine 

Related news

LW6 enhances chemosensitivity to gemcitabine (cas 103882-84-4) and inhibits autophagic flux in pancreatic cancer07/23/2019

The efficacy of gemcitabine therapy is often insufficient for the treatment of pancreatic cancer. The current study demonstrated that LW6, a chemical inhibitor of hypoxia-inducible factor 1α, is a promising drug for enhancing the chemosensitivity to gemcitabine. LW6 monotherapy and the combinat...detailed

Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine (cas 103882-84-4) resistance by reducing intracellular gemcitabine (cas 103882-84-4) metabolites07/22/2019

BackgroundCytosolic 5′-nucleotidase 1A (NT5C1A) dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates. Here, we investigate NT5C1A expression in pancreatic ductal adenocarcinoma (PDAC) and its impact on gemcitabine metabolism and therapeutic efficacy.detailed

HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine (cas 103882-84-4) by targeting ABCB107/20/2019

BackgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis, and gemcitabine-based chemotherapy remains an effective option for the majority of PDAC patients. Hepatocyte nuclear factor 1α (HNF1A) is a tumor-suppressor in PDAC, but its role in gemcitabine chemo...detailed

Digoxin sensitizes gemcitabine (cas 103882-84-4)-resistant pancreatic cancer cells to gemcitabine (cas 103882-84-4) via inhibiting Nrf2 signaling pathway07/21/2019

Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a cr...detailed

Relevant academic research and scientific papers

Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its use in the preparation of 2'-deoxy-2',2'-difluoro-β-D-ribofuranosyl pyrimidine nucleosides: The key role of selective crystallization

A stereospecific synthesis of 2'-deoxy-2',2'-difluorocytidine (gemcitabine), a potential anticancer agent, is described. The stereoselectivity was accomplished via two diastereoselective crystallizations, i.e. the crystallization of the key intermediate, difluororibonolactone 2a, and the crystallization of the hydrochloride salt of gemcitabine 16b from the anomeric mixture. Because of the availability of 2a in large quantities, other 2'-deoxy-2',2'-difluoropyrimidine nucleosides such as 2'-deoxy-2',2'-difluorouridine (19) were synthesized for structure-activity relationship studies.